Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 10751
Sealed predictions
- SLC37A1 in dopamine neurons, braak-0.65 (p 0.058) → +0.03 (p 0.929)receipt 10758
Swarm cases
receipt 10758: SLC37A1 in dopamine neurons, braak
- power
- full sample -0.35 (p 0.156, n 18), 95% CI -0.70 to +0.14. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.34 (p 0.167, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.49 (p 0.038, n 18). not the mix.
- skeptic
- leave-one-out range -0.51 to -0.27, sign flips 0; without severely affected donors -0.35 (p 0.156, n 18). fragile.
- cell type
- strongest in microglia: -0.65 (p 0.0034, n 18) vs -0.35 in dopamine neurons. proposing microglia.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SLC37A1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up SLC37A1 · microglia · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.20 p 0.477 (needs p < 2.1e-4)
Receipts
loading the receipts